| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-90 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 |
| filingDate |
2019-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e93b13763efb7aab4c9aac874c4467fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ee4a7c5ece9f59e221e45f5ca024f02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2877e11e6940689f041107b0faf53137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1065305a670192d3da468b13f0478fb6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a30fa3cb5f6d5f4e94447968982c388
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3062e89440a74ae805ea38a59a10745 |
| publicationDate |
2021-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-113227131-A |
| titleOfInvention |
Modified antibody Fc and methods of use thereof |
| abstract |
Biological macromolecules have great potential for the treatment of Central Nervous System (CNS) diseases, however, the presence of the Blood Brain Barrier (BBB) makes it extremely challenging to reach therapeutically relevant antibody concentrations. Antibodies with enhanced neutral pH affinity for neonatal Fc receptors exhibit improved accumulation in the brain. The variants disclosed herein also enhance exposure in engineered mouse models. These Fc variants significantly reduced brain a β levels by using anti-BACE 1 antibodies. |
| priorityDate |
2018-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |